Title: Impact of Nutrition Risk Index, Prognostic Nutritional Index and Skeletal Muscle Index
on early myelosuppression of first-line chemotherapy in stage IV gastric cancer patients
Version: 3 Date: 14 Nov 2024
Reviewer's report:
In this study, regimens of chemotherapy are not standardized. As pointed out by past reviewer,
this study evaluated a mix of cases treated with monotherapy (S-1/capecitabine) and doublet
therapy (SOX/XELOX). Therefore, it is unclear whether the
myelosuppression is due to chemotherapy or nutritional status.
Authors should standardize the use to either a single agent regimen or doublet regimen. If
authors want to explore the relationship between pre-chemotherapy nutritional state and early
myelosuppression, the regimen should be standardized, because the significant different in the
frequency of myelosuppression between monotherapy and doublet therapy.
Title: Impact of Nutrition Risk Index, Prognostic Nutritional Index and Skeletal Muscle Index
on early myelosuppression of first-line chemotherapy in stage IV gastric cancer patients
Version: 3 Date: 14 Nov 2024
Reviewer's report:
In this study, regimens of chemotherapy are not standardized. As pointed out by past reviewer,
this study evaluated a mix of cases treated with monotherapy (S-1/capecitabine) and doublet
therapy (SOX/XELOX). Therefore, it is unclear whether the
myelosuppression is due to chemotherapy or nutritional status.
Authors should standardize the use to either a single agent regimen or doublet regimen. If
authors want to explore the relationship between pre-chemotherapy nutritional state and early
myelosuppression, the regimen should be standardized, because the significant different in the
frequency of myelosuppression between monotherapy and doublet therapy.
Please review this paper.
user
Title: Impact of Nutrition Risk Index, Prognostic Nutritional Index and Skeletal Muscle Index
on early myelosuppression of first-line chemotherapy in stage IV gastric cancer patients
Version: 3 Date: 14 Nov 2024
Reviewer's report:
In this study, regimens of chemotherapy are not standardized. As pointed out by past reviewer,
this study evaluated a mix of cases treated with monotherapy (S-1/capecitabine) and doublet
therapy (SOX/XELOX). Therefore, it is unclear whether the
myelosuppression is due to chemotherapy or nutritional status.
Authors should standardize the use to either a single agent regimen or doublet regimen. If
authors want to explore the relationship between pre-chemotherapy nutritional state and early
myelosuppression, the regimen should be standardized, because the significant different in the
frequency of myelosuppression between monotherapy and doublet therapy.
assistant